The associations we observed between polymorphisms in RIPK1, RIPK3, and MAPKAPK2 genes and patient survival and treatment response reflect deeper biological relationships between genetic variants of necroptosis pathways and the pathophysiology of multiple myeloma. This evidence concerns the gene RIPK3 and plasma cell myeloma.